ADPT Adaptive Biotechnologies Corp Insider Trading

ADPT Chief Scientific Officer Harlan S Robins sells 492,400 shares for $10,780,408.80 via scheduled 10b5-1 plan

Harlan S Robins, Chief Scientific Officer, executed two separate sales totaling 492,400 shares for $10,780,408.80 on 2026-07-21 at a blended average price of $21.89 per share, reducing his non-derivative holdings from 1,304,458 shares to 812,058 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-13, meaning the execution was scheduled rather than discretionary. The stock currently trades at $22.31, within 3.6% of its 52-week high of $23.15, and has posted 30-day and 90-day returns of +29.5% and +57.8% respectively. Notably, the company reported revenue of $70,874,000 for the latest quarter with annual revenue growth of +54.8%, but remains unprofitable with net income of $-20,033,000 for its most recent full fiscal year—the sale occurs in a context of strong top-line growth alongside persistent losses.

CPO Francis Lo sells 105,762 ADPT shares at $22.59; retains 230,713 non-derivative shares plus 169,757 options outstanding.

Francis Lo, Chief People Officer of Adaptive Biotechnologies, sold 105,762 shares valued at $2,389,163.58 on 2026-07-15 through a pre-arranged 10b5-1 trading plan adopted on 2025-09-15—meaning this sale was scheduled, not discretionary. His non-derivative holdings fell 31.4% to 230,713 shares, but he retains 169,757 shares in derivative form (stock options), so his overall position remains material. The stock has gained 36.6% over the prior 30 days and 58.4% over 90 days, now trading at $22.92, just 1.0% below its 52-week high of $23.15. At the same ticker, Lo has executed five prior trades, including two additional sells three weeks before this filing (2026-07-02 and 2026-07-01); outcomes on those recent trades are not yet measurable. Fundamentally, the company reported quarterly revenue of $70.9M with annual growth of +54.8%, but remains unprofitable with a net loss of $-20.0M over its latest full fiscal year—a context in which scheduled, formulaic selling may warrant monitoring against the company's profitability trajectory.

Chief Scientific Officer Harlan Robins sells 386,240 shares for $8,501,148.79 under scheduled 10b5-1 plan, reducing stake by 27.5%

Harlan S Robins executed 2 sales totaling 386,240 shares on 2026-07-02 at a blended average price of $22.01, part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-13. This sale reduced his holdings from 1,405,898 shares to 1,019,658 shares, a 27.5% reduction in his stake at the company. The stock has risen 27.2% over the prior 30 days and 56.8% over 90 days, though the timing of this sale is determined by the pre-arranged schedule rather than discretionary judgment. While the company shows strong revenue growth of 54.8% year-over-year, it remains unprofitable with a net loss of $20,033,000 in the latest quarter, and the current stock price of $21.50 is 5.7% below the 52-week high, providing context for a significant insider reduction despite recent momentum.

ADPT Chief People Officer sells 95.8K shares for $2.2M via scheduled 10b5-1 plan; holds 230.7K shares post-sale

Francis Lo executed 3 separate sales totaling 95,842 shares for $2,157,682.66 on 2026-07-01 to 2026-07-02 at prices ranging from $22.18 to $22.59, as part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-15. His non-derivative holdings declined 29.3% from 326,555 to 230,713 shares, though he retains stock option holdings across multiple tranches. The current stock price of $21.50 sits 5.7% below the 52-week high of $22.80, and has climbed 27.2% over the prior 30 days and 56.8% over the prior 90 days. His prior sales at ADPT show mixed near-term outcomes: a June 2026 sale achieved 30-day gains of 21.2%, a March 2026 sale saw 30-day losses of 1.9% followed by 90-day gains of 6.0%, while January and December 2025 sales delivered negative 90-day returns of 27.9% and 15.4% respectively. ADPT remains unprofitable with net income of $-20,033,000.00 against quarterly revenue of $70,874,000.00, though annual revenue growth reached 54.8%.

Sharon Benzeno sells 165,802 shares (42.8% of holdings) at blended $21.13 via scheduled 10b5-1 plan

Sharon Benzeno, Chief Commercial Officer, executed 2 separate sales totaling 165,802 shares for $3,503,509.52 at an average price of $21.13 on June 26 and June 29, 2026, pursuant to a pre-arranged 10b5-1 trading plan adopted on December 12, 2025. Her non-derivative holdings fell to 221,278 shares post-transaction, though she retains 240,013 shares in derivative securities (stock options). The stock currently trades at $21.40, down 1.1% from its 52-week high of $21.64, and has gained 41.2% over 30 days and 54.2% over 90 days. The company is unprofitable with $-20.0M net income in the latest quarter despite strong revenue growth of 54.8% year-over-year, generating $70.9M in quarterly revenue. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects no timing signal about near-term stock prospects. Her prior open-market sells at this ticker (November 2025) showed modest positive 30-day returns but negative 90-day returns, suggesting a consistent pattern of selling into strength without predictive edge.

Director Michelle Renee Griffin sold 52,084 shares of ADPT at $20.18 (-1.1% from 52-week high) per pre-arranged 10b5-1 plan; retains 15,625 shares.

Director Michelle Renee Griffin executed a scheduled sale of 52,084 shares at $20.18 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing her non-derivative holdings from 67,709 shares to 15,625 shares. The sale occurred as the stock trades near its 52-week high of $21.64 (-1.1%) and amid significant recent momentum (+41.2% over 30 days, +54.2% over 90 days), yet the transaction was pre-planned rather than discretionary. Adaptive Biotechnologies remains unprofitable on a full-year basis (net income: $-20,033,000.00), though revenue growth has accelerated sharply at +54.8% year-over-year, creating a growth-at-loss profile. The timing coincides with the stock's elevated valuation relative to recent trading ranges, though the 10b5-1 framework precludes any inference about insider market timing or conviction.

CSO Harlan S Robins sells 106,160 shares for $1,847,941.60 under pre-arranged 10b5-1 plan at ADPT

Harlan S Robins, Chief Scientific Officer at Adaptive Biotechnologies, executed 2 separate sales totaling 106,160 shares for $1,847,941.60 on 2026-06-15 and 2026-06-16, reducing his holdings by 7.0% to 1,405,898 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-13, meaning it was scheduled rather than discretionary. At the time of sale, the blended average price of $17.41 was within the 52-week range of $9.90–$20.76, though currently the stock trades at $16.78, -19.2% from the 52-week high. Across his cross-ticker track record, Robins' prior 2 sells showed an average 90-day return of +31.8%, and at this same ticker (ADPT), his 2 prior trades on 2026-03-11 also showed +31.8% 90-day returns, though the scheduled nature of this transaction means timing characteristics do not apply to the filing itself. The underlying company reported $70.9M in quarterly revenue with annual growth of +54.8%, but remained unprofitable with -$20.0M net income, indicating this is a growth-stage biotech still advancing toward profitability.

CPO Francis Lo sells 39,741 ADPT shares at $17.49 under pre-arranged 10b5-1 plan; holds 250,934 shares post-sale plus 483,489 in stock options.

Francis Lo, Chief People Officer, executed a scheduled sale of 39,741 shares for $695,070.09 on 2026-06-04 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-15, meaning this was a non-discretionary, predetermined transaction. Lo retains 250,934 non-derivative shares post-transaction alongside derivative holdings totaling 483,489 shares across four stock option vehicles, so his overall economic exposure to ADPT remains substantial. The company faces significant near-term headwinds: it posted a net loss of $-20,033,000.00 on quarterly revenue of $70,874,000.00 and remains unprofitable on a full-year basis, despite strong annual revenue growth of +54.8%. The stock is down 19.6% from its 52-week high of $20.76, though it has recovered 20.9% over the prior 30 days and 15.0% over 90 days.

ADPT President/COO Rubinstein sells 57,180 shares in 3 trades (Apr 22-24) for $798,423.40; post-transaction holdings: 382,132 shares (-13.0%).

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed 3 separate sales totaling 57,180 shares for $798,423.40 between April 22 and April 24, 2026, at an average price of $13.96 per share. Her post-transaction holdings of 382,132 shares represent a -13.0% reduction from the 439,312 shares she held before these sales. The stock currently trades at $14.14, near the transaction prices, and is down 30.9% from its 52-week high of $20.46, suggesting a period of price deterioration despite the company's strong quarterly revenue of $93,973,000.00 and annual revenue growth of 54.8%. This sale activity occurs within a pattern of frequent selling activity at ADPT (5 prior trades in the same ticker within days of this filing), though outcomes on those prior trades are not yet measurable given their recent timing.

ADPT President & COO Julie Rubinstein sold 69,061 shares for $1,008,622.26 via scheduled 10b5-1 plan

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed 3 separate sales totaling 69,061 shares for $1,008,622.26 across April 17–21, 2026, at prices ranging from $14.55 to $14.66 with a blended average of $14.60. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-18, making it scheduled rather than discretionary. Her post-transaction holdings of 395,146 shares represent a 14.9% reduction from her pre-transaction holdings of 464,207 shares. The scheduled nature of this transaction removes any inference about executive sentiment or market timing on the sale.